Cingulate (NASDAQ:CING) Announces Quarterly Earnings Results, Beats Estimates By $0.17 EPS

Cingulate (NASDAQ:CING) released its earnings results on Tuesday. The company reported ($5.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($5.64) by $0.17, Zacks reports.

Cingulate Trading Down 12.4 %

Shares of Cingulate stock traded down $0.28 during trading on Wednesday, reaching $1.97. The company’s stock had a trading volume of 43,895 shares, compared to its average volume of 40,646. The business’s fifty day moving average price is $0.58 and its 200-day moving average price is $0.92. Cingulate has a one year low of $1.82 and a one year high of $187.20.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.